BRPI0519208A2 - derivados de pirrolinÍdio como receptores muscarÍnicos m3 - Google Patents

derivados de pirrolinÍdio como receptores muscarÍnicos m3

Info

Publication number
BRPI0519208A2
BRPI0519208A2 BRPI0519208-0A BRPI0519208A BRPI0519208A2 BR PI0519208 A2 BRPI0519208 A2 BR PI0519208A2 BR PI0519208 A BRPI0519208 A BR PI0519208A BR PI0519208 A2 BRPI0519208 A2 BR PI0519208A2
Authority
BR
Brazil
Prior art keywords
derivatives
pyrrolinium
muscarinic receptors
compounds
muscarinic
Prior art date
Application number
BRPI0519208-0A
Other languages
English (en)
Inventor
Neil John Press
Stephen Paul Collingwood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0519208A2 publication Critical patent/BRPI0519208A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DERIVADOS DE PIRROLINÍDIO COMO RECEPTORES MUSCARINICOS M3. A presente invenção refere-se a compostos de fórmula (1) na forma de sal ou zuiterlônica, em que R¹, R², Rü, R^ 4^ e R^ 5^ possuem os significados como indicado no relatório descritivo, são úteis para o tratamento de condições que são mediadas pelo receptor M3 muscarínico. Composições farmacêuticas que contêm os compostos e um processo para a preparação dos compostos são também descritas.
BRPI0519208-0A 2004-12-24 2005-12-22 derivados de pirrolinÍdio como receptores muscarÍnicos m3 BRPI0519208A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428416.2A GB0428416D0 (en) 2004-12-24 2004-12-24 Organic compounds
PCT/EP2005/013896 WO2006066928A1 (en) 2004-12-24 2005-12-22 Pyrrolinidium derivatives as m3 muscarinic receptors

Publications (1)

Publication Number Publication Date
BRPI0519208A2 true BRPI0519208A2 (pt) 2008-12-30

Family

ID=34130966

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519208-0A BRPI0519208A2 (pt) 2004-12-24 2005-12-22 derivados de pirrolinÍdio como receptores muscarÍnicos m3

Country Status (16)

Country Link
US (1) US8383625B2 (pt)
EP (1) EP1831202B1 (pt)
JP (1) JP2008525358A (pt)
KR (1) KR101256242B1 (pt)
CN (1) CN101087777B (pt)
AT (1) ATE541839T1 (pt)
AU (1) AU2005318423B2 (pt)
BR (1) BRPI0519208A2 (pt)
CA (1) CA2589744C (pt)
ES (1) ES2377486T3 (pt)
GB (1) GB0428416D0 (pt)
MX (1) MX2007007720A (pt)
PL (1) PL1831202T3 (pt)
PT (1) PT1831202E (pt)
RU (1) RU2412183C2 (pt)
WO (1) WO2006066928A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7417147B2 (en) 2005-11-10 2008-08-26 Bodor Nicholas S Soft anticholinergic zwitterions
WO2007058971A2 (en) 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic esters
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CA2675942C (en) 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
JP5656288B2 (ja) 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
US8017617B2 (en) 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
EP2935249B1 (en) 2012-12-19 2018-12-12 Novartis AG Autotaxin inhibitors
CN105050596A (zh) 2013-03-15 2015-11-11 博多尔实验仪器公司 用于治疗多汗症的抗胆碱能格隆溴铵酯
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US20170037030A1 (en) 2014-04-24 2017-02-09 Novartis Ag Autotaxin inhibitors
MY185814A (en) 2015-07-21 2021-06-10 Bodor Laboratories Inc Formulation for soft anticholinergic analogs
TWI719046B (zh) 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0937041B1 (de) 1996-11-11 2003-04-23 Christian R. Noe Verwendung eines pharmazeutisch geeigneten Salzes von (3R,2'R)-3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium zur Herstellung eines Arzneimittels
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR044851A1 (es) 2003-06-24 2005-10-05 Novartis Ag Compuestos heterociclicos, antagonistas del receptor m3 muscarinico
GB0428418D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
PL2227234T3 (pl) * 2007-10-15 2014-11-28 Can Fite Biopharma Ltd Sposób wywoływania proliferacji hepatocytów i jego zastosowania

Also Published As

Publication number Publication date
CN101087777A (zh) 2007-12-12
RU2007128080A (ru) 2009-01-27
EP1831202B1 (en) 2012-01-18
PT1831202E (pt) 2012-04-11
PL1831202T3 (pl) 2012-06-29
RU2412183C2 (ru) 2011-02-20
JP2008525358A (ja) 2008-07-17
ATE541839T1 (de) 2012-02-15
WO2006066928A1 (en) 2006-06-29
MX2007007720A (es) 2007-08-14
CN101087777B (zh) 2010-12-08
AU2005318423B2 (en) 2009-12-03
US8383625B2 (en) 2013-02-26
US20090291960A1 (en) 2009-11-26
AU2005318423A1 (en) 2006-06-29
CA2589744C (en) 2012-08-28
ES2377486T3 (es) 2012-03-28
GB0428416D0 (en) 2005-02-02
KR20070088730A (ko) 2007-08-29
KR101256242B1 (ko) 2013-04-17
EP1831202A1 (en) 2007-09-12
CA2589744A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
BRPI0410238A (pt) compostos orgánicos
BRPI0410037B8 (pt) inibidores de fosfatidilinositol 3-cinase, sua composição farmacêutica, e seu uso
BRPI0507034A (pt) compostos orgánicos
BRPI0413934A (pt) compostos orgánicos
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
BRPI0411738A (pt) compostos orgánicos
BRPI0916995B8 (pt) compostos orgânicos, seu uso, e composição farmacêutica
EA201000123A1 (ru) Органические соединения
BRPI0517945A (pt) derivados de quinuclidina e seu uso como antagonistas de receptor muscarìnico m3
MX2009004780A (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0809981A2 (pt) Compostos, processo de fabricação destes, composição farmacêutica que os contém, método de tratamento e/ou prevenção de doenças que são associadas a modulação de receptores de sst subtipo 5 e uso dos compostos.
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3
BRPI0519292A2 (pt) compostos orgÂnicos
BRPI0517455A (pt) compostos orgánicos
BRPI0713951B8 (pt) derivados de quinazolina, e composição farmacêutica
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
ATE450262T1 (de) Harnstoff-derivate als calcium-rezeptor- modulatoren
ATE550326T1 (de) Als modulatoren von hdl einsetzbare verbindungen
PL1745010T3 (pl) Podstawione pochodne cykloheksylo-1,4-diaminy
BRPI0518998A2 (pt) âmega-feniloctanamidas
TNSN05279A1 (en) Quinuclidine derivatives binding to mucarinic m3 receptors
BRPI0620694A2 (pt) composto, composição farmacêutica, processo para a preparação do composto, método para o tratamento de doenças inflamatórias mediado pela ativação de p38 map quinase e uso do composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.